Versant Ventures is gambling $12 million on a spinoff of the University of Basel with an in-house drug program that is angling to come up behind one of Novartis’s top mid-stage cancer assets.

…read more

Source: Versant gambles $12M on Swiss PI3K/mTOR cancer drug upstart